Section 5 of 6
Economic information and modeling report
21 evidence topics · 18 sources
Modeling overview
Summary: published economic evaluations
No cost-effectiveness analysis or budget impact model of rinzimetostat was identified. Published U.S. models address comparators and the combination partner. A partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel from a U.S. health care perspective (60-month horizon, 3% annual discount for costs, January 2025 dollars) estimated 0.86 versus 0.76 QALYs, mean total costs of $165,958 versus $129,700, and an ICER of $358,990 per QALY gained; results were most sensitive to the overall survival hazard ratio and the per-cycle costs of both treatments. Authors employed by Sanofi, the manufacturer of cabazitaxel, state that the model used the price of 177Lu-DOTATATE as a proxy for a per-cycle cost of $32,062. A U.S. payer cost model of third-line cabazitaxel versus a second androgen receptor-targeted agent over 18 months estimated $323,095 (17%) in avoided total costs, driven by the management of symptomatic skeletal events and end-of-life care; the CARD trial used cabazitaxel 25 mg/m2, while 20 mg/m2 is used in U.S. practice. A U.S. payer model of genomic test-directed olaparib after a new hormonal agent (2019 dollars) estimated an ICER of $116,903 per QALY in one scenario and cost savings in the other. For darolutamide, a U.S. payer budget impact model in nmCRPC for a 1-million-member plan over 5 years estimated a budget increase of $158,640 ($0.0132 PMPM) in year 1 and savings of $149,240 ($0.0124 PMPM) by year 5, and a U.S. hospitalization budget impact analysis of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer reported a cumulative budget impact of -$9.71 per treated member per month over 5 years.
Lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel: U.S. health care cost-effectiveness model
“In this study, we evaluated the impact of these benefits on the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A partitioned survival model was developed to estimate lifetime costs and health outcomes associated with 177Lu-PSMA-617 versus cabazitaxel over a 60-mo horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OS and PFS associated with177Lu-PSMA-617 were derived from a retrospective cohort, and relative treatment effects (hazard ratios [HRs]) from the TheraP trial were applied to generate outcomes for patients treated with cabazitaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis was conducted over a lifetime horizon of 60 mo with a 1-mo cycle length on the basis that over 99% of patients in our model transitioned to a terminal state within this period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An annual discount of 3% for costs was applied in the analysis in accordance with recommendations from the Second U.S. Panel on Cost-Effectiveness in Health and Medicine (17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were adjusted to January 2025 U.S. dollars using the medical care component of the Consumer Price Index (23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base case analysis, 177Lu-PSMA-617 was associated with an average of 0.86 QALYs, compared with 0.76 QALYs for cabazitaxel. The mean total costs were $165,958 for 177Lu-PSMA-617 and $129,700 for cabazitaxel, resulting in an incremental cost of $36,258 and an incremental QALY gain of 0.10. This corresponded to an ICER of $358,990/QALY gained, exceeding the highest U.S. WTP threshold of $200,000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost-effectiveness results were most sensitive to the OS HR, the per-cycle cost of 177Lu-PSMA-617, and the per-cycle cost of cabazitaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At WTP thresholds of $50,000/QALY, $100,000/QALY, and $200,000/QALY, the corresponding maximum cost per cycle that would make 177Lu-PSMA-617 cost-effective was $23,499, $24,885, and $27,656, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic analyses found that 177Lu-PSMA-617 was cost-effective in 19.7% of iterations at a WTP threshold of $200,000/QALY, 4.7% at $100,000/QALY, and 2.2% at $50,000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acquisition cost input of the lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model
“The authors note that direct U.S. cost data for 177Lu-PSMA-617 were not available and therefore used the price of 177Lu-DOTATATE as a proxy, citing a pan-Canadian Oncology Drug Review (pCODR) report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base-case per-cycle cost for 177Lu-PSMA-617 was $32,062, with a sensitivity range of $25,649–$38,474, reflecting a 20% variation around the base case (i.e., 80%–120%), consistent with the underlying Advanced Accelerator Applications model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the directional conclusion is unlikely to change, the magnitude of difference is likely greater than reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kyle Flannery, Paul Cavanaugh, and Kevin Steele are employees of Sanofi, the manufacturer of Jevtana (cabazitaxel) injection, and may hold shares or options in the company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cabazitaxel versus a second androgen receptor-targeted agent after docetaxel and an androgen receptor-targeted agent: U.S. payer cost model
“We aimed to estimate healthcare costs avoided with the use of cabazitaxel as a third-line (3 L) treatment versus a second ARTA from a US payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the short life expectancy for the target population (median OS of 11.0–13.6 months) [19], a time horizon of 18 months was used for the reference case analysis, and scenario analyses were conducted for time horizons of 6, 12, and 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The economic analysis included the costs associated with the management of SSEs, AEs, and end-of-life care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cabazitaxel, as compared with a second ARTA, was associated with 58 fewer hospitalization days and 2 fewer ICU days and was estimated to avoid $323,095 (€274,630, 17%) in total costs, driven by SSEs management and end-of-life care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CARD trial evaluated the 25 mg/m2 dose of cabazitaxel, while 20 mg/m2 is routinely used in clinical practice in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genomic test-directed olaparib after a new hormonal agent: U.S. payer cost-effectiveness model
“We aimed to evaluate the cost-effectiveness of genomic test-directed olaparib on MCRPC from the US payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A mathematical model combining a decision tree and partitioned survival model was established to measure the clinical and economic outcomes of olaparib and standard care for men with MCRPC who had disease progression while receiving a new hormonal agent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct medical costs were considered from a United States payer perspective, which was reported in 2019 United States dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Darolutamide in nonmetastatic castration-resistant prostate cancer: U.S. payer budget impact model
“A budget impact model was developed to evaluate darolutamide for nmCRPC for a hypothetical 1-million-member plan over a 5-year period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs (drug acquisition, drug administration, and treatment-related adverse events [AEs]) were estimated for 2 scenarios: with and without darolutamide treatment for nmCRPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Market share estimates were derived from interviews with physicians treating men with nmCRPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For a plan with 1 million lives, there were approximately 90 incident cases of nmCRPC (46 high risk) each year, with 332 (109 high risk) treatment-eligible cases by year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the utilization of other agents, introducing darolutamide along with other targeted therapies was predicted to increase the total budget by $158,640 ($0.0132 per member per month [PMPM]) in year 1, which decreased over time to a cost savings of $149,240 ($0.0124 PMPM) by year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Darolutamide with docetaxel in metastatic hormone-sensitive prostate cancer: U.S. hospitalization budget impact analysis
“Based on these estimates, a budget impact analysis evaluated the hospitalization costs (including ICU admissions) and standalone ICU hospitalization costs for the totality of the US population over a 5-year time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The budget impact per treated member per month represents a cost-neutral option after Year 5 with a cumulative budget impact of -$9.71.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
Company estimate of the annual U.S. population with mCRPC previously treated with abiraterone
Abiraterone share of new androgen receptor pathway inhibitor prescriptions
Modeled annual U.S. incidence of mCRPC
“The model estimated the prevalence of prostate cancer as 2,219,280 in the US in 2009 and 3,072,480 in 2020, and incidence of mCRPC as 36,100 and 42,970, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The nmCRPC clinical state contributed heavily to the mCRPC states (86%), while the incidence flow from the non-castrate state to mCRPC was <15%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Androgen receptor pathway inhibitor use before mCRPC diagnosis and as first-line mCRPC treatment
“Before mCRPC diagnosis, most patients (73.9% [3963/5361]) had not received treatment intensification; 867 (16.2%) had received prior ARPi only; 448 (8.4%), prior taxane only; and 83 (1.5%), both prior ARPi and taxane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment by line of therapy among Medicare beneficiaries with mCRPC
“22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common therapies were abiraterone (36%), enzalutamide (28%), and docetaxel (16%) for 1 L; enzalutamide (33%), abiraterone (28%), and docetaxel (15%) for 2 L; and docetaxel (24%), enzalutamide (19%), and abiraterone (17%) for 3 L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For 37% of all mCRPC patients, NHTs were the only life-prolonging therapy they received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost assumptions
Medicare Part B payment limits for parenteral comparators and bone-targeted agents, October to December 2026
| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
|---|---|---|---|---|
| J9043 cabazitaxel (Jevtana) | “Cabazitaxel injection” | “1 MG” | “231.688” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| Q2043 sipuleucel-T (Provenge) | “Sipuleucel-t auto cd54+” | “Per infusion (minimum 50 million cells)” | “55663.131” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J0897 denosumab (Xgeva) | “Denosumab injection” | “1 MG” | “29.856” | “17.885” |
| J3489 zoledronic acid | “Zoledronic acid 1mg” | “1 MG” | “17.673” | “20.000” |
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1 microCurie” | “N/A” | “20.000” |
Radium-223 dichloride: payment limit note in the Medicare Part B file
Hospital outpatient payment rates for radiopharmaceuticals, October 2026
| HCPCS code and product | Short descriptor | APC | Payment rate | Minimum unadjusted copayment |
|---|---|---|---|---|
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1745” | “$180.422” | “$36.09” |
| A9607 lutetium Lu 177 vipivotide tetraxetan (Pluvicto) | “Lutetium lu 177 vipivotide” | “9054” | “$266.541” | “$53.31” |
Lutetium Lu 177 vipivotide tetraxetan: per-dose cost estimated from Medicare Administrative Contractor payment rates
“We collected all identifiable MAC payment rates for 177Lu-PSMA-617 (HCPCS A9607) across publicly available MAC jurisdictions (JE, JF, JJ, JM, J6, JK, and J15), standardized rates to a per-millicurie basis, and used the median to reduce outlier influence. Assuming the use of a 200-mCi dose, this yielded an estimated per-dose cost of $55,522 (3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although 177Lu-PSMA-617 was approved by the Food and Drug Administration in March 2022 (7), there remains no ASP-based benchmark for this agent within the CMS ASP framework; under the current reimbursement structure, such a benchmark would not be expected to emerge absent U.S. legislative or regulatory change (4–6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Per-cycle costs in the U.S. lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model
| Input | Base case value (USD) | Range for sensitivity analysis (USD) |
|---|---|---|
| Cost per cycle, lutetium Lu 177 vipivotide tetraxetan | “32,062”View highlighted excerpt for this quote | “25,649–38,474”View highlighted excerpt for this quote |
| Cost per cycle, cabazitaxel | “14,382”View highlighted excerpt for this quote | “11,505–17,852”View highlighted excerpt for this quote |
| Gallium Ga 68 PSMA PET/CT | “5,689”View highlighted excerpt for this quote | “4,551–6,829”View highlighted excerpt for this quote |
| End of life | “17,312”View highlighted excerpt for this quote | “13,849–20,773”View highlighted excerpt for this quote |
Darolutamide wholesale acquisition cost
| Product and package | Manufacturer | Drug product description | WAC effective date | WAC increase amount (USD) | WAC after increase (USD) |
|---|---|---|---|---|---|
| Nubeqa (darolutamide) 300 mg, 120 tablets | “Bayer” | “Nubeqa 300 mg tab 120 count” | “2026-01-01T00:00:00” | “847.20” | “15100.80” |
Enzalutamide: Medicare negotiated price effective January 2027 and 2024 list price
| Drug | Participating drug company | Agreed to negotiated price for 30-day supply for CY 2027 | List price for 30-day supply, CY 2024 | Discount of negotiated price from 2024 list price |
|---|---|---|---|---|
| Xtandi (enzalutamide) | “Astellas Pharma US, Inc.” | “$7,004” | “$13,480” | “48%” |
Company price assumption in the post-abiraterone addressable market estimate
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
Summary: inputs available and absence of a rinzimetostat price or model
No budget impact model of rinzimetostat was identified, and no rinzimetostat price has been published: ORIC has “no products approved for commercial sale”, and its $3.5 billion U.S. addressable market figure “assumes current price of ARPIs for illustrative purposes”. A plan building its own model would need the rinzimetostat price and the regimen studied in Himalayas-1, rinzimetostat 400 mg once daily with darolutamide 600 mg twice daily. Published population inputs are ORIC's estimate of approximately 17,000 U.S. patients annually with mCRPC previously treated with abiraterone (company-reported), a modeled U.S. mCRPC incidence of 42,970 in 2020, and Medicare fee-for-service data in which abiraterone accounted for 36% of first-line mCRPC therapy and 42% of men received at least two lines. Published cost inputs are the darolutamide wholesale acquisition cost of $15,100.80 per bottle of 120 tablets of 300 mg (effective 1 January 2026), the 2027 Medicare negotiated price for enzalutamide of $7,004 per 30-day supply, and Medicare Part B payment limits for October to December 2026 for docetaxel ($0.471 per mg) and cabazitaxel ($231.688 per mg).